Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Conditions
Brief summary
This randomized phase II trial studies how well pemetrexed disodium with or without erlotinib hydrochloride works in treating patients with stage IIIB-IV or recurrent non-small cell lung cancer. Drugs used in chemotherapy, such as pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether pemetrexed disodium is more effective with or without erlotinib hydrochloride in treating non-small cell lung cancer.
Detailed description
PRIMARY OBJECTIVES: I. To evaluate progression free survival (PFS) in the schedule-modulated concomitant administration of erlotinib (erlotinib hydrochloride) and pemetrexed (pemetrexed disodium), and in single agent pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) as second-line chemotherapy. SECONDARY OBJECTIVES: I. To evaluate antitumor objective response rate (complete response \[CR\] + partial response \[PR\]) per Response Evaluation Criteria in Solid Tumors (RECIST) criteria. II. To evaluate disease control rate (response rate + stable disease, i.e., CR+PR+ stable disease \[SD\]) and duration of response. III. To evaluate median time to progression (TTP) and overall survival (OS). IV. To evaluate the safety profile of concurrent pemetrexed and erlotinib versus single agent pemetrexed. TERTIARY OBJECTIVES: i. To determine several molecular and cellular biomarkers in the tumors, the skin and the serum that are predictive of the efficacy of pemetrexed and erlotinib. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM A: Patients receive pemetrexed disodium intravenously (IV) over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. ARM B: Patients receive pemetrexed disodium IV as in Arm A and erlotinib hydrochloride orally (PO) once daily (QD) on days 2-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 12 months.
Interventions
DRUGErlotinib Hydrochloride
Given PO
OTHERLaboratory Biomarker Analysis
Correlative studies
DRUGPemetrexed Disodium
Given IV
Sponsors
National Cancer Institute (NCI)
Eli Lilly and Company
OSI Pharmaceuticals
Albert Einstein College of Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have histologically or cytologically confirmed advanced (stage IIIB with a malignant pleural effusion or stage IV disease) or recurrent nonsquamous NSCLC * Patients must have at least one measurable disease per RECIST criteria; all sites of disease must be assessed within 4 weeks prior to registration * Patient must have disease progression after one prior combinational chemotherapy and/or targeted therapy other than pemetrexed or an epidermal growth factor receptor (EGFR) ) tyrosine kinase inhibitor (TKI) (such as erlotinib, gefitinib, or a second generation EGFR TKI); prior monoclonal antibody against EGFR is allowed) for metastatic disease, or relapse while receiving adjuvant therapy, or within 12 months of completing adjuvant therapy * All patients will be screened for brain metastasis within 6 weeks prior to registration; patients with treated and stable brain metastases must have been treated with surgery and/or radiation and are asymptomatic and are no longer taking corticosteroids * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 or Karnofsky \>= 60% * Absolute neutrophil count \>= 1,500/uL * Hemoglobin \>= 8.0 g/dL * Platelets \>= 100,000/uL * Total bilirubin =\< 1.5 x institutional upper limit of normal (ULN), except in known hepatic metastasis, wherein may be =\< 3.0 X ULN * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 3.0 x institutional ULN, except in known hepatic metastasis, wherein may be =\< 5.0 X ULN * Creatinine clearance \>= 45 mL/min for patients with creatinine levels above institutional normal * Patients must not be pregnant or breastfeeding since there is no information regarding the use of these agents in this population; a negative serum or urine pregnancy test is required within 14 days prior to registration if pre- or perimenopausal (i.e., last menstrual period within one year of registration); both pemetrexed and erlotinib are Class D agent with the potential for teratogenic or abortifacient effects; patients both females and males with reproductive potential (i.e. menopausal for less than 1 year and not surgically sterilized) must practice contraceptive measures throughout the study * Patients taking Warfarin or nonsteroidal anti-inflammatory drugs (NSAIDs) are eligible; patients with mild to moderate renal insufficiency should avoid taking NSAIDs with short elimination half-lives for a period of 2 days before, the day of, and 2 days following administration of Alimta; if the patient is taking other cytochrome P450 3A4 (CYP3A4) inducers or inhibitors, they must be discontinued at least one week prior to starting erlotinib * Ability to understand and the willingness to sign a written informed consent document
Exclusion criteria
* Patients who have had immunotherapy, hormone, chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier * Patients who have received pemetrexed or an EGFR TKI (such as erlotinib, gefitinib, or a second generation anti-EGFR TKI) for their metastatic disease should be excluded from this clinical trial; other molecularly targeted agent, including monoclonal antibody or vaccine against EGFR or angiogenesis inhibitor, is allowed * Patients may not be receiving any other investigational or commercial agents or therapies other than those described below with the intent to treat the patient's malignancy * Patients with uncontrolled brain metastases should be excluded from this clinical trial because of their poor prognosis * History of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib or pemetrexed or other agents used in the study * Patients with gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease, are ineligible * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (such as bacteremia or active hepatitis), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy; therefore, human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with erlotinib or pemetrexed or other agents administered during the study; appropriate studies will be undertake in patients receiving combination anti-retroviral therapy when indicated
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PFS (Progression Free Survival) | Time from randomization until documented tumor progression or death from any cause, assessed up to 12 months | Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (CR +PR) Evaluated Using RECIST | Up to 12 months | Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR Response rates in each arm will be summarized by computing proportions and corresponding 95% confidence intervals. |
| Overall Survival | Time from the date of randomization to date of death due to any cause, assessed up to 12 months | Time to event endpoints will be analyzed using standard survival analytic methods, including the Kaplan-Meier approach for estimating the survival distributions. |
Countries
United States
Participant flow
Recruitment details
Patients with platinum-treated metastatic non squamous NSCLC randomly assigned 1:2 to pemetrexed alone (500 mg/m\^2 provided iv on day 1) or pemetrexed followed by erlotinib (150 mg provided orally daily on days 2-17) every 21 days.
Participants by arm
| Arm | Count |
|---|---|
| Arm A (Pemetrexed) Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Pemetrexed Disodium: Given IV | 27 |
| Arm B (Pemetrexed Disodium, Erlotinib Hydrochloride) Patients receive pemetrexed disodium IV as in Arm A and erlotinib hydrochloride PO QD on days 2-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Erlotinib Hydrochloride: Given PO
Laboratory Biomarker Analysis: Correlative studies
Pemetrexed Disodium: Given IV | 52 |
| Total | 79 |
Baseline characteristics
| Characteristic | Arm A (Pemetrexed) | Arm B (Pemetrexed Disodium, Erlotinib Hydrochloride) | Total |
|---|---|---|---|
| Age, Continuous | 64 years | 62 years | 63 years |
| ECOG PS ECOG PS 0 | 24 participants | 46 participants | 70 participants |
| ECOG PS ECOG PS 1/2 | 3 participants | 6 participants | 9 participants |
| Evaluable patients with atleast one source of biospecimen Archival tumor specimens | 6 participants | 14 participants | 20 participants |
| Evaluable patients with atleast one source of biospecimen Collected blood samples | 17 participants | 32 participants | 49 participants |
| Evaluable patients with atleast one source of biospecimen EGFR (epidermal growth factor receptor) mutations | 0 participants | 7 participants | 7 participants |
| Evaluable patients with atleast one source of biospecimen EGFR (epidermal growth factor receptor) wild type | 21 participants | 31 participants | 52 participants |
| Evaluable patients with atleast one source of biospecimen Unkown EGFR (epidermal growth factor recep) status | 4 participants | 12 participants | 16 participants |
| Histology: Nonsquamous Prior antiangiogenic inhibitor | 10 participants | 18 participants | 28 participants |
| Histology: Nonsquamous Prior platinum-containing chemotherapy | 27 participants | 50 participants | 77 participants |
| Race/Ethnicity, Customized Asian | 0 participants | 2 participants | 2 participants |
| Race/Ethnicity, Customized Black | 5 participants | 9 participants | 14 participants |
| Race/Ethnicity, Customized Hispanic | 4 participants | 6 participants | 10 participants |
| Race/Ethnicity, Customized White | 18 participants | 36 participants | 54 participants |
| Sex: Female, Male Female | 13 Participants | 29 Participants | 42 Participants |
| Sex: Female, Male Male | 14 Participants | 23 Participants | 37 Participants |
| Smoking history <=15 pack-years | 5 participants | 17 participants | 22 participants |
| Smoking history >15 pack-years | 22 participants | 35 participants | 58 participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 25 | 0 / 50 |
| other Total, other adverse events | 25 / 25 | 50 / 50 |
| serious Total, serious adverse events | 9 / 25 | 16 / 50 |
Outcome results
Primary
PFS (Progression Free Survival)
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
Time frame: Time from randomization until documented tumor progression or death from any cause, assessed up to 12 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A (Pemetrexed) | PFS (Progression Free Survival) | 8 months |
| Arm B (Pemetrexed Disodium, Erlotinib Hydrochloride) | PFS (Progression Free Survival) | 20 months |
Secondary
Objective Response Rate (CR +PR) Evaluated Using RECIST
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR Response rates in each arm will be summarized by computing proportions and corresponding 95% confidence intervals.
Time frame: Up to 12 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm A (Pemetrexed) | Objective Response Rate (CR +PR) Evaluated Using RECIST | 12 percentage of participants |
| Arm B (Pemetrexed Disodium, Erlotinib Hydrochloride) | Objective Response Rate (CR +PR) Evaluated Using RECIST | 28 percentage of participants |
Secondary
Overall Survival
Time to event endpoints will be analyzed using standard survival analytic methods, including the Kaplan-Meier approach for estimating the survival distributions.
Time frame: Time from the date of randomization to date of death due to any cause, assessed up to 12 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm A (Pemetrexed) | Overall Survival | 25 Participants |
| Arm B (Pemetrexed Disodium, Erlotinib Hydrochloride) | Overall Survival | 50 Participants |